For research use only. Not for therapeutic Use.
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.
| Catalog Number | I047426 |
| Purity | ≥95% |
| Reference | [1] Boni V, et al. Clin Cancer Res. 2022 May 13;28(10):2020-2029. |
